New Compass Pathways patents granted?
Another US patent was granted on March 16, 2021
This is Compass’ second US patent, in same family as the first patent granted on December 31, 2019
New ‘257 patent: patft.uspto.gov/netacgi/nph-Pa…
First ‘175 patent: patft.uspto.gov/netacgi/nph-Pa…
1/7
Another US patent was granted on March 16, 2021
This is Compass’ second US patent, in same family as the first patent granted on December 31, 2019
New ‘257 patent: patft.uspto.gov/netacgi/nph-Pa…
First ‘175 patent: patft.uspto.gov/netacgi/nph-Pa…
1/7
A primary difference between the new ‘257 & the first ‘175 patent is:
– ‘175 patent claims methods “of treating drug resistant depression” by orally administering “an oral dosage form“ of the COMP360 psilocybin Polymorph A
– ‘257 patent claims the “oral dosage form” itself
2/7
– ‘175 patent claims methods “of treating drug resistant depression” by orally administering “an oral dosage form“ of the COMP360 psilocybin Polymorph A
– ‘257 patent claims the “oral dosage form” itself
2/7
Just as with the first ‘175 patent, the new ‘257 patent claims the psilocybin Polymorph A by reference to its “XRPD diffractogram”
These are the peaks displayed when the polymorph is analyzed by X-ray
Compass unsuccessfully sought claims without these XRPD limitations
3/7
These are the peaks displayed when the polymorph is analyzed by X-ray
Compass unsuccessfully sought claims without these XRPD limitations
3/7
https://twitter.com/calyxlaw/status/1319409977291751425
One important difference in Compass’ new ‘257 patent is the addition of broader method of treatment claims:
The ‘175 claims are all limited to “drug resistant depression”
The ‘257 claims are directed to “major depressive disorder”
4/7
The ‘175 claims are all limited to “drug resistant depression”
The ‘257 claims are directed to “major depressive disorder”
4/7
Compass’ new patent issued relatively quickly—in 237 days, compared to average pendency of nearly 2 years
It was a “Track One” application, where extra fees are paid for prioritized examination
Compass appears to have 3rd app also granted—so quickly it hasn’t yet published
5/7
It was a “Track One” application, where extra fees are paid for prioritized examination
Compass appears to have 3rd app also granted—so quickly it hasn’t yet published
5/7
Compass has another continuation application, filed on February 10, 2021, that is also not yet public
In total, from this single family, Compass has:
–First ‘175 patent
–New ‘257 patent
–Additional patent not yet published
–Pending app on mfg
–Additional unpublished app
6/7
In total, from this single family, Compass has:
–First ‘175 patent
–New ‘257 patent
–Additional patent not yet published
–Pending app on mfg
–Additional unpublished app
6/7
Besides this patent family, there are 3 more still at the PCT stage
Application file for new ‘257 patent: patentcenter.uspto.gov/#!/application…
Follow along with Compass Pathways’ patent applications and granted patents on the @PsilocybinAlpha Patent Tracker
7/7
psilocybinalpha.com/data/psilocybi…
Application file for new ‘257 patent: patentcenter.uspto.gov/#!/application…
Follow along with Compass Pathways’ patent applications and granted patents on the @PsilocybinAlpha Patent Tracker
7/7
psilocybinalpha.com/data/psilocybi…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
